← Leaderboards
Milton H. Werner
Rockefeller University
$15,360,237
Attributed
$15,360,237
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$15,360,237 · 10
By mechanism
R44$11,752,318 · 3
R01$2,326,007 · 2
R43$1,273,713 · 4
P41$8,199 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsSafetyNovel StrategiesCellsAntineoplastic AgentsBiological ProductsSite Directed MutagenesisPropertyLeadBrainInhibitor/AntagonistIn VivoSmall Business Innovation Research GrantTyrosine Kinase InhibitorDrug KineticsPhosphotransferasesImatinibCessation Of LifePreparationPhysical ModelNuclear Magnetic Resonance SpectroscopyAdverse EffectsOralAnimal Model
Grant awards (26)
Kinase activation in multiple system atrophy$385,888
R43 · FY2021 · NS · contact PI
Advanced therapeutic for Parkinson's Disease$1,546,730
R44 · FY2020 · NS · contact PI
Advanced therapeutic for Parkinson's Disease$1,554,108
R44 · FY2019 · NS · contact PI
Advanced Prodrug Treatment for CML$985,960
R44 · FY2019 · CA · contact PI
Advanced therapeutic for Parkinson's Disease$1,554,563
R44 · FY2018 · NS · contact PI
Advanced Prodrug Treatment for CML$1,016,040
R44 · FY2018 · CA · contact PI
Advanced PML antiviral$1,000,000
R44 · FY2018 · AI · contact PI
Advanced therapeutic for Parkinson's Disease$1,554,020
R44 · FY2017 · NS · contact PI
Advanced PML antiviral$1,000,000
R44 · FY2017 · AI · contact PI
Prodrug treatment for CML$284,778
R43 · FY2017 · CA · contact PI
Novel DFG out inhibitors of Abl-kinases to treat PML$787,776
R44 · FY2016 · AI · contact PI
Novel DFG out inhibitors of Abl-kinases to treat PML$753,121
R44 · FY2015 · AI · contact PI
DFG-out inhibitors of Abl-kinases to treat PML$300,000
R43 · FY2013 · AI · contact PI
PML antiviral for AIDS$37,201
R43 · FY2010 · NS · contact PI
PML antiviral for AIDS$265,846
R43 · FY2009 · NS · contact PI
Stuctural basis of polymerase recruitment to promoters$267,200
R01 · FY2005 · GM
Structure and Function of the Death Effector FADD$250,500
R01 · FY2005 · GM
Stuctural basis of polymerase recruitment to promoters$267,200
R01 · FY2004 · GM
Structure and Function of the Death Effector FADD$250,500
R01 · FY2004 · GM
Stuctural basis of polymerase recruitment to promoters$267,200
R01 · FY2003 · GM
Structure and Function of the Death Effector FADD$250,500
R01 · FY2003 · GM
Stuctural basis of polymerase recruitment to promoters$267,200
R01 · FY2002 · GM
Structure and Function of the Death Effector FADD$245,475
R01 · FY2002 · GM
Stuctural basis of polymerase recruitment to promoters$260,232
R01 · FY2001 · GM
MECHANISMS OF PROGRAMMED CELL DEATH$0
P41 · FY2001 · RR
MECHANISMS OF PROGRAMMED CELL DEATH$8,199
P41 · FY2000 · RR